Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/genes8020051 http://scihub22266oqcxt.onion/10.3390/genes8020051 C5333040!5333040!28134780     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Genes+(Basel) 2017 ; 8 (2): ä Nephropedia Template TP {{tp|p=28134780|t=2017. Viral Vector-Mediated Antisense Therapy for Genetic Diseases |pdf=|usr=}}{{28134780}} gab.com Text Viral Vector-Mediated Antisense Therapy for Genetic Diseases JO: Genes (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=28134780 #FOAvip RNA plays complex roles in normal health and disease and is becoming an important target for therapeutic intervention; accordingly, therapeutic strategies that modulate RNA function have gained great interest over the past decade. Antisense oligonucleotides (AOs) are perhaps the most promising strategy to modulate RNA expression through a variety of post binding events such as gene silencing through degradative or non-degradative mechanisms, or splicing modulation which has recently demonstrated promising results. However, AO technology still faces issues like poor cellular-uptake, low efficacy in target tissues and relatively rapid clearance from the circulation which means repeated injections are essential to complete therapeutic efficacy. To overcome these limitations, viral vectors encoding small nuclear RNAs have been engineered to shuttle antisense sequences into cells, allowing appropriate subcellular localization with pre-mRNAs and permanent correction. In this review, we outline the different strategies for antisense therapy mediated by viral vectors and provide examples of each approach. We also address the advantages and limitations of viral vector use, with an emphasis on their clinical application. Twit Text FOAVip Viral Vector-Mediated Antisense Therapy for Genetic Diseases ????Genes (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=28134780 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28134780 #FOAvip English Wikipedia <ref>{{Cite pmid|28134780}}</ref> Viral Vector-Mediated Antisense Therapy for Genetic Diseases #MMPMID28134780 Imbert M; Dias-Florencio G; Goyenvalle A Genes (Basel) 2017[Feb]; 8 (2): ä PMID28134780show ga RNA plays complex roles in normal health and disease and is becoming an important target for therapeutic intervention; accordingly, therapeutic strategies that modulate RNA function have gained great interest over the past decade. Antisense oligonucleotides (AOs) are perhaps the most promising strategy to modulate RNA expression through a variety of post binding events such as gene silencing through degradative or non-degradative mechanisms, or splicing modulation which has recently demonstrated promising results. However, AO technology still faces issues like poor cellular-uptake, low efficacy in target tissues and relatively rapid clearance from the circulation which means repeated injections are essential to complete therapeutic efficacy. To overcome these limitations, viral vectors encoding small nuclear RNAs have been engineered to shuttle antisense sequences into cells, allowing appropriate subcellular localization with pre-mRNAs and permanent correction. In this review, we outline the different strategies for antisense therapy mediated by viral vectors and provide examples of each approach. We also address the advantages and limitations of viral vector use, with an emphasis on their clinical application. äViral Vector-Mediated Antisense Therapy for Genetic Diseases (epmc).pdf DeepDyve Pubget Overpricing